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Objectives. In-hospital peripheral vascular complications of 
balloon angioplasty were compared with those f directional 
atherectomy in the Coronary Angioplasty Versus Excisional 
Atherectomy Trial (CAVEAT.I) to identify patients a  risk and 
evaluate costs and outcomes. 
Background. The incidence, costs and outcomes of peripheral 
vascular complications after coronary intervention have not been 
fully characterized as a function of randomly assigned therapy. 
Methods. At 35 sites in the United States and Europe, 1,012 
patients were randomized. Peripheral vascular complications 
were defined as the composite of pulse loss, pseudoaneurysm, 
hematoma >4 cm in diameter o  groin hemorrhage necessitating 
blood transfusion. Logistic models were derived to 1) predict these 
complications from baseline and procedural characteristics, 2) 
test the relevance of randomization assignment, and 3) assess 
their impact on hospital costs and long-term outcomes. 
Results. Sixty-seven patients (6.6%) developed peripheral vas- 
cular complications, of whom 15 (22.4%) required a blood trans- 
fusion, 14 (20.9%) underwent vascular surgery, and 2 (3.0%) died. 
Both in-hospital deaths occurred in patients with peripheral 
vascular complications. There was no difference in composite 
peripheral vascular complication rates among patients random- 
ized to angioplasty or atherectomy. Greater age, female gender, 
postprocedural heparin nd intraaortic balloon counterpulsation 
were predictive of increased risk. In a representative 60% subset, 
mean hospital costs increased from $9,583 in patients without to 
$18,350 in those with peripheral vascular complications (p = 
0.0001). The unadjusted mortality ra eat 1 year was 7.5% for 
patients with peripheral vascular complications compared with 
1.1% for all others (p = 0.0001). These complications identified 
patients at greater risk of death, myocardial infarction or repeat 
revascularization at 30 days and 1 year. The atherectomy group 
had a trend toward more frequent deaths and myocardial infarc- 
tion. 
Conclusions. Directional atherectomy and balloon angioplasty 
had similar in-hospital peripheral vascular complication rates. 
Female gender, greater age, postprocedurai heparin and intr aor- 
tic balloon counterpulsation were predictive of higher risk. The 
twofold increase in cost and sevenfold increase in long-term 
deaths highlight the need to prevent these periprocedural events 
and monitor patients closely. 
(J Am CoU Cardio11995;26:922-30) 
Peripheral vascular complications have beenreported from the 
earliest days of percutaneous cardiac atheterization a d have 
been estimated o occur in 0.7% to 9% of patients in observa- 
tional analyses (1-14). They include access-site h matomas 
(with or without extension), thromboembolic occlusions, 
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pseudoaneurysms, arteriovenous fi tulas, infection and neura- 
praxia. The consequences of such complications i clude blood 
loss requiring volume, vasopressor or transfusion support 
(15,16); vascular surgery (with attendant morbidity and mor- 
tality) (17); longer hospital stays with greater nursing require- 
ments; and higher in-hospital and long-term rehabilitation 
costs (14). There are also potential medicolegal ramifications 
(18). 
Directional coronary atherectomy was approved in 1990 by 
the Food and Drug Administration asan alternative topercu- 
taneous transluminal coronary (balloon) angioplasty for reliev- 
ing coronary atherosclerotic obstructions. It typically requires 
larger (10F to llF) arterial sheaths an balloon angioplasty 
(-<8F) and takes longer to perform (19-21). Rather than 
simple dilation as in coronary angioplasty, directional coronary 
atherectomy is based on the principles of cutting, collecting 
and removing plaque from the affected coronary artery. Al- 
though directional coronary atherectomy is the second most 
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widely practiced form of coronary intervention after balloon 
angioplasty in the United States, there are no randomized trial 
data in the published reports directly comparing their vascular 
complication profiles. 
The randomized Coronary Angioplasty Versus Excisional 
Atherectomy Trial (CAVEAT-I) tested the hypothesis that 
atherectomy is superior to balloon angioplasty (21). Atherec- 
tomy generally resulted in a larger initial target lumen size and 
a lower rate of angiographic restenosis at 6 months. However, 
these angiographic outcomes were achieved at the expense of
more frequent coronary ischemic complications and higher 
in-hospital costs. Furthermore, no net clinical advantage (in- 
cluding the need for repeat revascularization) was discernible 
at 6 months (21) or at 1-year follow-up (22). 
Although peripheral vascular complications were not a 
specified primary outcome measure, data were prospectively 
collected. The purpose of the present report is to characterize 
peripheral vascular complications in CAVEAT-I on the basis 
of baseline characteristics, treatment assignment and peripro- 
cedurai factors. We evaluated hospital costs as well as the 
independent impact of these events on 30-day and 1-year 
clinical outcomes (death, myocardial infarction and repeat 
revascularization). 
Methods 
CAVEAT-I. The design, methods, enrollment statistics and 
major findings of CAVEAT-I have been published in detail 
previously (21). Briefly, 1,012 patients with clinically significant 
coronary artery disease deemed suitable for percutaneous 
intervention using either ->3.0-ram balloon angioplasty or ---6F 
atherectomy catheter (Atherocath) were enrolled at 35 sites 
in the United States and Europe. Enrollment began on 
August 15, 1991 and was completed on April 30, 1992. 
Angioplasty and atherectomy were performed according to 
standard techniques (19,20). All principal investigators had to 
have performed at least 50 directional atherectomies and >400 
balloon angioplasties to qualify for participation. 
All patients received aspirin, and heparin was administered 
in a bolus of 10,000 U with additional doses to maintain the 
activated clotting time >350 s during the procedure. Femoral 
access heaths were removed from 4 to 24 h after the proce- 
dure on the basis of standardized protocols at each random- 
ization site. 
End points. The primary end point of CAVEAT-I was 
angiographic restenosis at 6 months after an initially successful 
procedure (<50% residual stenosis ascertained by a central 
angiographic core laboratory). An early clinical end point was 
prospectively defined as the composite of death, emergency 
coronary artery bypass surgery, acute myocardial infarction 
and abrupt vessel closure during the index hospital period. The 
6-month clinical end point, prospectively defined as the cumu- 
lative composite of death, myocardial infarction, bypass ur- 
gery or need for subsequent coronary intervention, was subse- 
quently extended to 1-year follow-up. An economic and quality 
of life substudy was performed on a prospective basis with 606 
patients at 19 of the 32 U.S. study sites. As described previ- 
ously (21), all hospital bills covering the period from enroll- 
ment through the 6-month follow-up were collected prospec- 
tively for these patients. Hospital charges were converted to 
costs using the revenue center-specific cost/charge ratios and 
per diems from each ospital's Medicare cost report. 
Study data. All data were prospectively recorded at study 
sites on case report forms that were then submitted to the 
Duke University coordinating center. After double data entry, 
range and consistency checks were performed. All case report 
forms were compared with procedure reports and discharge 
summaries. A random 15% sample of all forms was audited 
against complete source medical records. 
Statistical analysis. Peripheral vascular complications were 
defined for the purpose of this study as the composite of pulse 
loss, pseudoaneurysm, hematoma >4 cm in diameter or groin 
hemorrhage necessitating blood transfusion. Categoric data 
are presented as percent of patients and continuous data as 
medians (25th, 75th percentiles). On the basis of a review of 
published reports, a et of baseline clinical characteristics (age, 
gender, height, weight, diabetes, hypertension, history of pe- 
ripheral vascular disease and current smoking) and periproce- 
dural characteristics (procedure duration, sheath duration, 
total number of catheterizations, use of coumadin, adjunctive 
thrombolytic therapy, use of an intraaortic balloon pump, use 
of heparin and maximal activated clotting time) were prespeci- 
fled along with randomization assignment for evaluation of 
their abilities to predict vascular complications. Univariable 
analyses of these variables were performed using logistic 
regression. To avoid using variables (e.g., repeat catheteriza- 
tion) that occurred after a preceding vascular complication to 
predict a vascular complication, postprocedural variables for 
patients with a vascular complication were truncated so that 
any occurring after a vascular complication were discounted. 
This method created a differential time window of opportunity 
for occurrence of variables between patients with and without 
a vascular complication. Therefore, periprocedural variables 
were truncated for all patients at 18.58 h (the average time to 
vascular complication occurrence after the start of the proce- 
dure), and analyses were repeated. Results were consistent. 
Multivariable logistic regression models were developed to 
evaluate the joint effect of the specified predictors on vascular 
complications as well as the differential effect of randomized 
treatment assignment with these predictors (23). Separate 
models were developed forclinical and periprocedural f ctors. 
In each, a global test of the interactions of treatment with the 
other main effects was performed. Because there was no 
evidence of significant differential reatment effects, only mod- 
els of the main effects were created using stepwise and 
backward techniques. The exact replication of results using 
either selection technique provided some insurance about he 
stability of the final model. The clinical and periprocedural 
models were then combined to create a final model for the 
prediction of vascular complications. 
Short- (30 day) and long-term (1 year) models were estab- 
lished to reflect the complete clinical consequence of any 
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Table 1. Peripheral Vascular Complications as a Function of 
Baseline Clinical and Angiographic Characteristics 
Characteristic 
No Vascular Vascular 
Complications Complications 
(n = 945) (n = 67) 
Age (yr) 59 (51,661 64 (55, 69) 
Male gender 73.9 55.2 
Weight (kg) 82.0 (72.7, 931 78.(I (70.0, 87.5) 
Height (cm) 172.7(165.1,178.11) 167.6 (162.6, 175.0) 
Diabetes 19.4 I 1.9 
Current smoker 28.8 20.9 
Hypertension 52.4 56.7 
Cholesterol (mg/dl) 216 ( 189, 248) 221 (194, 252) 
History of Ml 42.9 43.3 
Unstable angina 68.4 67.2 
Ejection fraction 60 (5il. (~51 60 (50, 62) 
No. of diseased vessels 
1 65.2 59.7 
2 29.2 37.3 
3 5 .f~ 3.0 
Thrombus 18,b 24.6 
Lesion lcngth (mm) 8.9 (6.5, 12.0) 8.6 (6.7, 10.8) 
Vessel caliber (ram) 2.76 (2.41,3.11) 2.80 (2.47, 3.23) 
% stennsis 72.1) (62.8, 78. I) 72.2 (64. I, 811.2) 
Data presented are percent of patients or median (25th, 75th percentiles). 
Table 3. Peripheral Vascular Complications as a Function of 
In-Hospital Outcomes* 
Vascular No Vascular 
Outcome Complications Complications 
Death 3.0 0 
Myocardial infarction 
Detected by site 10.4 4.7 
Q wave 4.5 1.4 
Non-Q wave 5.9 3.3 
Detected by adjudication 17.2 10.2 
(abnormal enzyme levels only) 
Emergency CABG 3.0 2.4 
Abrupt vessel closure 14.9 5.3 
Early-phase composite end point 16.4 7.9 
*Includes death, acute myocardial infarction, emergency coronary artery 
bypass surgery (CABG) and abrupt vessel closure. Data presented are percent of 
patients. 
tial effect of treatment on outcome. The additional significance 
of the occurrence of a vascular complication after adjusting for 
these important variables was evaluated first by including the 
interactions of the vascular complication with all the variables 
in each model and second by including the vascular complica- 
tion as an additional main effect in each model. 
differences in specified outcome. Modcls of in-hospital and 
long-term clinical outcomes had previously been developed to 
be used as baseline predictive clinical models for all reports. 
Logistic regression was used to evaluate events at 30 days, and 
Cox proportional hazard modeling techniques were used for 
1-year outcomes. The models were based on baseline clinical 
factors, treatment, angiographic results as well as the differen- 
Resu l ts  
Descriptive results. Baseline characteristics, technical fea- 
tures and results of the procedures have previously been 
described (21). Tables 1 to 3 illustrate the distribution of 
peripheral vascular complications as a function of baseline 
characteristics, technical features and in-hospital outcomes. 
Table 2. Peripheral Vascular Complications as a Function of Technical Features and Results of 
the Procedures 
Procedural Feature 
Vascular Complications No Vascular Complications 
DCA PTCA DCA PTCA 
(n = 34) (n := 33) (n = 478) (n = 467) 
Maximal size of equipment 
Athercctomy cutter 
5F II 
~F 56.2 
7F 43.8 
Balloon catheter (mm) 
<3.11 
3.0-4.(I 
>4.0 
Use of opposite technique 17.6 
Use of perfuskm balloon 14.7 
Stent or laser use 2.9 
Use of any other device 29.4 
Final % stenosis 
Visually assessed 
Quantitatively assessed 
Minimal lumen diameter (mm) 
Perforation 
m 1.1 
52.11 
47,(I 
m 
20 (1i!, 25) 2(1 (19.5, 28.5) 15 (10, 20) 20 (10, 30) 
33.1 (27.0, 40.6) 42.5 (33.1, 47.2) 33.4 (24.9, 41.8) 40.7 (33.5, 48.6) 
1.87 (1.59, 2.28) 1.75 (1.38, 2.04) 1.89 (1.55, 2.17) 1.64 (1.42, 1.98) 
I) 0 0.42 0.21 
Data presented arc percent of patients or median (25th, 75th percentiles). DCA = directional coronary atherectomy; 
PTCA = percutaneous transluminal corona~ (balloon) angioplasty. 
9.4 - -  7.8 
90.6 - -  91.5 
O.0 - -  0.a5 
3.(1 18.6 4.3 
12.1 1/t.5 10.7 
3.0 1.0 0.21 
18.2 25.9 14.4 
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Vascular surgery 
Groin hemorrhage 
with transfusion 
Hematoma > 4 cm 
Pseudoaneurysm 
Pulse Loss 
N 
PTCA I 
DCA 
]7.9 
IS2.4 
~-- ]  17.6 
o 2o ~ 6o 80 ~o 
Frequency (%) 
Figure 1. Bar chart illustrating the relative distribution of specific 
peripheral vascular complications as a function of randomized assign- 
ment. The term peripheral vascular complication was defined as the 
composite of pulse loss, pseudoaneurysm, hematoma >4 cm in diam- 
eter or groin hemorrhage necessitating blood transfusion. See text for 
discussion. DCA = directional corona~, atherectomy; PTCA = per- 
cutaneous transluminal coronary angioplasty. 
Sheath size and site were not specifically recorded for each 
patient, but directional coronary atherectomy use implies 
larger sheath sizes, and use of femoral access sites was 
universal. 
A total of 67 (6.6%) of 1,012 patients had a peripheral 
vascular complication, f whom 15 (22.4%) had a blood 
transfusion, 14 (20.9%) underwent vascular surgery, and 2 
(3.0%) died. Pulse loss (defined as the absence of previously 
palpable distal pulses) occurred in 11.9%, and pseudoaneu- 
rysms in 10.4% of these patients. Over 85% of patients had a 
hematoma >4 cm in diameter (Fig. 1). The unadjusted 1-year 
mortality rates were 7.5% for patients with a vascular compli- 
cation and 1.1% for others (p = 0.0001). Patients undergoing 
directional coronary atherectomy and those undergoing coro- 
nary angioplasty bad a vascular complication rate of 6.6% 
(intention to treat comparison, p = 0.98). 
Among patients with peripheral vascular complications, 
>80% had a hematoma >4 cm in diameter (Fig. 1). Univari- 
able baseline clinical variables that were significantly predictive 
Table 5. Vascular Complications as a Function of Other Baseline 
and Procedural Factors Tested 
No Vascular Vascular 
Complications Complications p 
(n = 945) (n = 67) Value* 
Diabetes 
Hypertension 
History of peripheral 
vascular disease 
Procedure duration (h) 
Duration to sheath 
removal (h) 
Maximal ACT (s) 
Postprocedural warfarin 
Adjunct thrombolysis 
Repeat catheterization 
19.4 11.9 0.114 
52.4 56.7 0.491 
6.0 3.0 0.260 
1.67 (1.25, 2.17) 1.75 (1.25, 2.42) 0.161 
10.75 (7.08, 18.58) 14.83 (7.20, 18.58) 0.286 
367 (294, 422) 369 (304, 419) 0.821 
5.0 6.0 0.725 
1.9 3.0 0.566 
5.2 7.5 0.446 
*Based on log-likelihood chi-square statistics (univariate). Data presented 
are percent of patients or median (25th, 75th percentiles). ACT = activated 
clotting time. 
of complications (p < 0.05) were female gender, older age, 
lower body surface area, shorter height and lower weight. The 
only procedural covariate found predictive of increased risk on 
univariable analysis (Tables 4 and 5) was postprocedural 
heparin. In general, the use of mechanical support devices was 
uncommon. Intraaortic balloon counterpulsation showed a 
nonsignificant univariate association with vascular complica- 
tions (p = 0.075). Although there was a trend toward a longer 
median time to sheath removal among patients with a vascular 
complication, this was not statistically significant (14.83 vs. 
10.75 h, p = 0.286). 
In a multivariable logistic model combining baseline at-
tributes and procedural covariates, postprocedural heparin, 
intraaortic balloon counterpulsation, female gender and age 
were found to be independently predictive of complications 
(Table 6). From an overall perspective, every increase in age of 
1 year increased the risk of a peripheral vascular complication 
by 3%. However, patients >65 years old had twice the vascular 
complication rate of younger patients (9.6% vs. 5.05%, multi- 
variate association, p = 0.03). Among women, the vascular 
Table 4. Univariable Predictors of Vascular Complications 
Vascular Complications No Vascular Complications 
DCA PTCA DCA PTCA 
Variable (n = 34) (n = 33) (n = 478) (n = 467) p Value* 
Age (yr) 60 (52, 68) 67 (61, 73) 59 (51, 67) 58 (51, 66) 0.004 
Female gender 44.1 45.5 23.6 28.7 0.002 
BSA (m:) 1.91(1.8,2.0) 1.87(1.8,1.9) 1.96(1.8,2.1) 1.95(1.8,2.1) 0.017 
Smoking history. 67.7 48.5 69.9 69.1 0.060 
Weight (kg) 79 (71, 88) 77 (70, 83) 82 (73, 92) 82 (72, 94) 0.043 
Height (cm) 168 (163. 175) 168 (165, 177) 173 (166, 179) 173 (165, 178) 0.031 
IABP 8.8 3.(I 2.3 1.7 0.075 
Postprocedural heparin 64.7 72.7 49.8 61.7 0.035 
*Based on log-likelihood chi-square statistics (univariate). Data presented are percent of patients or median (25th, 
75th percentiles). BSA - body surface area: IABP - intraaortic balloon pump; other abbreviations a in Table 2. 
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Table 6. Multivariable Logistic Regression Analysis of Predictors of 
Peripheral Vascular Complications 
Odds p 
Variable Coetficient Ratio Value ~ 
Baseline model (chi-squarc 19.55) 
Intercept 4.44/)3 
Age 0,11273 1.028 0.032 
Female gender 0.7964 2.218 0.0030 
Diabetes -0,7875 0.455 0.045 
Postprocedural model 
(chi-square 7.51 )
Intercept 3.03119 
Balloon counterpulsation 1.1135 3.045 0.050 
Postprocedural heparin I).5518 1.736 0.042 
Combined baseline and 
postprocedural model 
(chi-square 27.00) 
Intercept 4.9216 
Age 0.0288 1.029 I).1i25 
Female gender 0.7816 2.185 0.004 
Diabetes -11.780t) 0.458 0.1149 
Balloon counterpulsation 1.1779 3.247 0.[141 
Postprocedural heparin 0.5408 1.717 0.049 
*Based on log-likelihood chi-square statistics. 
complication rate was 10.8% compared with 5.8% for men 
(p = 0.003). Diabetes was associated with a lower incidence of 
vascular complications, and previous peripheral vascular dis- 
ease was not a significant predictor. No interactions were 
found between randomization assignment and either baseline 
variables or procedural covariates. 
Patients in the conomics and quality of life substudy were 
similar to those not included in the substudy (Table 7). Mean 
hospital costs and lengths of stay for the 606 patients in
economics and quality of life substudy are shown in Table 8 
(categorized by peripheral vascular complications). The occur- 
rence of such complications was an independent predictor of 
increased costs (p = 0.0001). 
Consequences. Among all patients in the study, irrespec- 
tive of vascular complication, excluding those who underwent 
bypass surgery, the median decrease in hematocrit among 
patients randomized to directional coronary atherectomy was 
3.8% (1.6, 6.3 [25th, 75th percentiles]) in comparison with 
3.4% (1.0, 6.0) among patients randomized tocoronary angio- 
plasty (p = 0.163). In the directional coronary, atherectomy 
group, 22 patients received packed-cell transfusions compared 
with 14 patients randomized to coronary angioplasty (p = 
0.182). 
Two deaths occurred among patients with in-hospital vas- 
cular complications (3.0%) compared with no deaths in the 
rest of the study group. In one patient, multiple transfusions 
were required for groin bleeding after thrombolysis, whereas 
another required bilateral above-knee amputation for limb 
ischemia. At 1 year, the cumulative death r te among these 
patients had risen to 7.5% compared with 1.1% among patients 
free of such a complication (p = 0.0001). Moreover, patients 
who had a vascular complication made up 50% of all those who 
Table 7. Characteristics ofPatients in the Economic and Quality of 
Life Substudy Compared With Those of All Other Patients 
Non- p Value 
EQOL EQOL (EQOL vs. 
Characteristic (n = 606) (n = 406)  non-EQOL) 
DCA 50 51 0.662 
Diabetes 21 16 0.057 
Hypertension 53 52 0.623 
History., of PVD 5 6 0.532 
History of smoking 68 69 0.793 
Female gender 31 23 0.006 
Weight (kg) 82 81 0.236 
(73, 94) (72, 91) 
Height (cm) 173 173 0.056 
(105, 178) (168, 178) 
Age (yr) 59 59 0.930 
(51, 67) (52, 66) 
Cholesterol (mg/dl) 215 217 0.151 
(186, 246) (193, 252) 
BSA (m 2) 1.95 1.95 0.918 
(1.82, 2.10) (1.83, 2.08) 
Peripheral vascular 7 6 0.317 
complications 
Aspirin 99 98 0.113 
Warfarin 5 6 0.457 
Thrombolysis 1 2 0.351 
Repeat catheterization 6 5 0.668 
IABP 2 2 0.597 
Procedure duration (h) 1.75 1.58 0.008 
(1.25, 2.25) (1.25, 2.07) 
Sheath duration (h) 11.1 10.8 0.702 
(7.0, 18.6) (7.3, 18.6) 
Maximal ACT (s) 374 349 0.003 
(306, 429) (253, 403) 
Maximal aPTI' (s) 75 79 0.960 
(34, 231) (56, 100) 
Data presented are percent of patients or median (25th, 75th percentiles). 
aPTI" = activated partial thromboplastin time; EQOL = economic and quality 
of life substudy; PVD = peripheral vascular disease; other abbreviations as in 
Tables 2. 4 and 5. 
died at 1 year. Table 9 summarizes the clinical profiles of 
patients with vascular complications whodied during 1 year. 
Table 10 illustrates the independent effect of vascular 
complications on clinical outcomes at 30 days and 1 year. The 
occurrence of in-hospital vascular complications identified a 
groupof patients with a higher long-term likelihood of death, 
myocardial infarction or repeat revascularization. Patients with
a previous myocardial infarction who had a peripheral vascular 
complication had a nonsignificant trend toward higher com- 
posite event rates. 
D iscuss ion  
The present study. In the CAVEAT-I experience, despite 
differences in sheath size and procedure time, directional 
atherectomy and balloon angioplasty had similar overall rates 
of peripheral vascular complications (6.6%) and vascular sur- 
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Table 8. Mean Hospital Costs and Length of Stay for 606 Patients 
Categorized by Presence or Absence of Peripheral 
Vascular Complications 
No Vascular Vascular 
Complications Complications p 
(n 562) (n = 44) Value 
Total hospital cost ($) 9,583 18,3511 11.00(11 
Room 1,178 4,556 
Intensive care unit 2,030 3.6gt~ 
Catheterization laboratory 2,8(17 3.933 
Laboratory 448 t,136 
Pharmacy 450 997 
Radiography/nuclear 144 412 
Operating 201/ 59 I
room/anesthesia 
Blood bank 20 110 
Medical supplies 1,525 1,930 
Respiratory, therapy 78 189 
Electrocardiogram 140 221) 
Total hospital charges ($) 15,494 2g,0t)3 0.0001 
Length of stay 
Total 5.2 days 12.1 days 0.0001 
Intensive care unit 2.5 days 4.5 days 0.005 
gery (2.1%). These complications were associated with twice- 
higher hospital costs. Trends toward greater equirements for 
blood transfusions and a higher incidence of pulse loss among 
patients randomized to directional coronary atherectomy were 
balanced by the higher incidence of pseudoaneurysm among 
patients randomized to coronary angioplasty. However, the 
finding that patients randomized to directional coronary 
atherectomy had a pattern of higher overall transfusion rates, 
groin hemorrhage requiring transfusion, peripheral pulse loss 
and coronary ischemic events raises concern. The data suggest 
that serious long-term complications (death or myocardial 
infarction) were more likely among patients with a vascular 
complication if they had initially been randomized to direc- 
tional coronary atherectomy. Neither of the two patients 
randomized to coronary angioplasty who died in hospital 
underwent directional coronary atherectomy; however, they 
did cross over to other treatments. 
Women and older patients were at greatest risk for com- 
plications, and postprocedural heparin and use of intraaortic 
balloon counterpulsation were independent procedural factors 
linked to complications. There was a nonsignificant trend 
toward greater interaction between age and vascular compli- 
cations among patients randomized to coronary angioplasty 
(but not directional coronary atherectomy), and smoking 
showed a trend toward greater interaction with directional 
coronary atherectomy (but not coronary angioplasty). Surpris- 
ingly, diabetic patients were at lower risk. Indeed, there were 
no differences in pulse loss or groin hemorrhage rates for 
diabetic patients, indicating that both thrombotic and hemor- 
rhagic events were similarly less frequent in this group. Per- 
haps most intriguing was the significance of these complica- 
tions as an independent marker for adverse long-term 
outcomes. 
Table 9. Clinical Profile of Patients With Peripheral Vascular 
Complications Who Died Within 1 Year* 
Procedure Age (yr)/Gender Clinical Summary 
PTCA 63/F Abrupt closure; thrombolytic therapy; 
retroperitoneal hematoma; multiple 
transfusions; ARDS and multisystem 
failure; Q wave MI; cardiogenic shock 
PTCA 62/M Abrupt in-laboratory side-branch occlusion; 
IABP/emergency CABG; subsequent 
bilateral bove-knee amputation; 
respiratory failure 
DCA 59/F Discharged with >4 cm hematoma at sheath 
site; readmitted forpulmonary emboli 
DCA 78/F Abrupt closure in LAD/LCx; LAD reopened; 
VT,NF. Readmitted with pulmonary 
edema: left lower limb ischemia; multiple 
vascular surgical procedures; possible 
bowel infarction 
DCAt 65/F Pseodoaneurysm diagnosed after discharge; 
recurrence of angina t 2 mo; atrial 
fibrillation followed by asystolic arrest 2
days after vascular surgery 
DCA 76/F Femoral artery thrombus surgically removed; 
recurrent acute hypotension, heart block 
during follow-up; tamponade secondary to 
right ventricular perforation bytemporary 
pacing wire 
*Adapted from Ellion et al. (22). #Peripheral vascular complication detected 
after initial discharge. ARDS - adult respiratory distress yndrome; CAD = 
coronary artery disease; F = female; LAD - left anterior descending coronary 
artery; LCx - left circumflex coronary, artery; M - male; MI = myocardial 
infarction: VF = ventricular fibrillation; VT = ventricular tachycardia; other 
abbreviations as in Tables 2 to 4. 
Previous studies. Several observational studies (1-14) have 
attempted to define the relative incidence, predictors and 
implications of peripheral vascular complications. With e 
introduction of new devices for coronary revascularization, 
these complications have become important outcome mea- 
sures. CAVEAT-I was the first randomized coronary device 
trial conducted and thus presented a unique opportunity to 
compare these complications after directional coronary 
atherectomy and coronary angioplasty. 
The observed incidence of peripheral vascular complica- 
tions in CAVEAT-I was at the higher end of the range of 
reported rates (Table 11). The wide range probably reflects 
differences in definitions, study populations and accuracy of 
documentation. In CAVEAT-I, all case report forms were 
audited against catheterization, procedure and discharge re- 
ports. A 15% random sample was audited against all medical 
records. Double data entry was performed, and all variables 
used in subsequent reports and presentations underwent com- 
puterized ata checks. The monitoring committee has consis- 
tently been satisfied with the quality of data collection, verifi- 
cation and entry. Because ours is the only detailed report with 
independent monitoring of the data, it is conceivable that the 
prevalence of these complications may be underappreciated in 
practice. 
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Table 10. Effect of Peripheral Vascular Complications onClinical Outcomes 
Overall Group 
No Vascular Complications Vascular Complications No Vascular Vascular 
Outcome DCA PTCA DCA PTCA Complications Complications p Value* 
30-d death/Ml 32 (6.7) 15 (3.2) 5 (14.7) 2 (6.1) 47 (5.0) 7 (10.5) 0.06 
30-d death/MI/CABG 46 (9.6) 21 (4.5) 5 (14.7) 3 (9.1) 67 (7.1) 8 (11.9) 0.16 
30-d death/MI/revascularization 61 (12.8) 35 (7.5) 7 (20.6) 7 (21.2) 96 (10.2) 14 (20.9) 0.01 
1-yr death/Ml 45 (9.4) 22 (4.7) 8 (23.5) 3 (9.1) 67 (7.1) 11 (16.4) 0.006 
1-yr death/Ml/CABG 85 (17.8) 58 (12.4) 10 (29.4) 6 (18.2) 143 (15.1) 16 (23.9) 0.04 
1-yr death/MI/revascularization 199 (41.6) 180 (38.5) 20 (58.8) 17 (51.5) 379 (40.1) 37 (55.2) 0.002 
*Adjusted for randomization assignment and significant baseline clinical factors. Data presented are number (%) of patients. CABG = coronary artery bypass 
surgery; d = day; MI = myocardial infarction; revascularization = bypass urgeD', angioplasty or atherectomy. 
Risk factors. The finding that women and older patients 
had higher baseline risk confirms theobservations of others. 
Some (but not all) studies (7,11) have also pointed out 
increased risk in diabetic and hypertensive patients and smok- 
ers. Our inability to confirm this may have been due to reduced 
statistical power. The contribution of postprocedural anticoag- 
ulation has also been previously reported (9,12,13,24). Our 
finding that previous peripheral vascular disease did not pre- 
dict complications is at odds with some studies (11) but in 
agreement with others (14). 
Approximately 19% and 5.8% of the entire study group had 
diabetes and previous peripheral vascular disease at b line, 
respectively. That these factors did not predict vascular com- 
plications may relate to greater caution and attention to detail 
in these patients among participating investigators and hospi- 
tals, which is supported by the lower rate of vascular compli- 
cations among diabetic patients in this and other reported 
analyses (7,11). However, the relative insensitivity of clinical 
markers for detection of peripheral vascular disease (25) may 
Table 11. Published Reports of Vascular Complication Rates 
Study (ref no.) No. of Pts 
Overall Vascular 
Rate Surgery 
Balloon angioplasty 
Dorros et al. (2) 1,5i~0 1.5 NR 
Wyman et al. (4) 933 2.6 1.5 
Muller ct al. (11) 698 2.6 1].7 
Kresowik et al. (9) 144 9.0 NR 
Oweida et al. (7) 4.988 NR 1.0 
Skillman et al. (3) 1,747 NR 0.9 
Kaufman et al. (6) 644 0.9 0.5 
Popma et al. (12) 154 3.2 1.9 
Fischman et al. (42) 203 4.5 2.0 
Serruys et al. (43) 131 3. I NR 
CAVEAT-I (21) 500 6.6 2.1 
Atherectomy 
Safian et al. (8) 67 NR 3.0 
Popma et al. (12) 3(13 3.6 1.9 
Moscucci et aI. (13) 375 6.S 5.1 
CAVEAT-I (21) 512 6,6 2.1 
CAVEAT Coronary. Angioplas U Versus Excisional Atherectomy Trial: 
NR = not reported; Pts = patients; ref - reference. 
have resulted in an underestimation f its prevalence in the 
study patients. 
The similarity in complication rates between coronary 
angioplasty and directional coronary atherectomy (despite 
larger sheath size used for atherectomy) was also observed in 
the study of Popma et al. (12), although others (11) have 
reported conflicting results. It does appear that after control- 
ling for other baseline and procedural factors, sheath size 
(within the 8F to 10F range) itself is not an independent 
determinant of composite vascular complications. In a recent 
report (13), smaller sheaths used for stenting were associated 
with higher complication rates than larger sheaths u ed for 
directional atherectomy. This finding was ascribed to antico- 
agulation. Our finding that peripheral vascular complications 
were associated with a twofold increase in total hospital costs 
resulting from greater resource use across all major cost catego- 
ries has not been previously described in published reports. 
Prevention and treatment. The trend for directional coro- 
nary atherectomy to be associated with a igher incidence of 
pulse loss is a reminder that we need to be sensitive to the 
effects of putting large catheters into small vessels. This trend 
is reinforced by previously reported vascular complication 
rates from large mechanical support devices (26). Although 
not statistically significant, thetrends toward higher overall 
transfusion rates and greater eduction in hematocrit among 
patients randomized to directional coronary atherectomy also 
emphasize the need for more attentiveness to blood loss during 
these procedures. We have no data to explain the lower 
frequency of pseudoaneurysms in patients randomized to 
directional coronary atherectomy; however, it may reflect 
better attention t  insertion technique because operators were 
aware of the sheath size (27). This observation should be 
interpreted cautiously, however, because CAVEAT-I was not 
prospectively designed to evaluate these complications. The 
possibility of physician-specific bias in the frequency of obtain- 
ing imaging studies in response to clinical suspicion cannot be 
excluded (9,28,29). 
The impact of anticoagulation vascular complications 
identifies an area of decision making potentially amenable to 
modification. In a recent study from the Cleveland Clinic (14), 
for example, only 50% of the patients maintained on hepa- 
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rin after intervention had an established indication. The 
CAVEAT-I experience suggests that indications for continuing 
heparin after intervention eed to be clarified, and algorithms 
for optimal anticoagulation i  relevant circumstances need to 
be developed. Subcutaneous rather than intravenous adminis- 
tration of heparin may reduce the incidence of hematomas 
(30). Attention to proper techniques of early sheath removal 
guided by activated clotting time has been observed to reduce 
risks in some studies (31). Indeed, in our study there was a 
trend toward longer duration of sheath placement among 
patients with a vascular complication. Cautious patient mobi- 
lization has been advocated by others (32). 
If postprocedural nticoagulation is anticipated, one ap- 
proach is to extend compression longer than with routine 
cases; C-clamp and Femostop devices may be helpful. How- 
ever, excessive compression can cause thrombosis. Sedatives, 
stool softeners, antitussives, antiemetics and pressure dressings 
are helpful adjuncts to proper immobilization. In patients who 
require repeat catheterization, simple measures, uch as using 
alternate access ites (10), compression bandaging of previ- 
ously used sites (33), giving attention to entry technique (34), 
selective use of antibiotic prophylaxis and avoidance of blood 
loss (particularly through the Y-adapter), may be helpful. 
Vascular plugs could become a useful adjunct in the future 
(35). 
Clinical implications. Patients with peripheral vascular 
complications had a significantly increased independent risk of 
adverse long-term outcomes (Table 10). Possible explanations 
include the morbidity and mortality inherent in vascular com- 
plications and the therapeutic nterventions they trigger (trans- 
fusions and vascular surgery). In this scenario, complications 
appear to beget complications (Table 9). Alternatively, vascu- 
lar complications and adverse long-term coronary outcomes 
may be different manifestations of a common clinical substrate. 
It is probably simplistic to consider the coronary tree in 
isolation from other parts of the vascular system. The indepen- 
dent effect of peripheral vascular disease on long-term risk 
among coronary patients, for example, is well established 
(38,39). The role of coronary events in long-term outcomes of 
patients with large-vessel peripheral vascular disease has also 
been reported (38,39). 
Peripheral vascular complications may at least in part be an 
indicator of overall patient response to current echniques of 
percutaneous intervention. The severity of this response may 
highlight a more diffusely diseased or abnormal vasculaturc 
than previously classified peripheral vascular disease, pure 
angiographic stratification of coronary disease and lumen 
results of intervention encompass. Whatever the explanation, 
the results of CAVEAT-1 strongly suggest that these compli- 
cations should be vigorously prevented and affected patients 
followed up more closely than has hitherto been appreciated 
by the cardiology community (40). Peripheral vascular complica- 
tions should be collated as part of operator- and hospital-specific 
data in the emerging environment of scorecard cardiovascular 
medicine (41). Our findings may also have implications for 
designing future clinical trials. 
Study limitations. We used a composite definition of pe- 
ripheral vascular complications to maximize event capture. 
The present study was not adequately powered to critically 
examine differences in more narrowly defined hemorrhagic or 
thromboembolic vascular complications. There is a possibility 
that results reported therein may therefore be due to chance. 
In addition, a number of baseline variables of potential interest 
were not evaluated because of missing or incomplete data. 
They include the high density lipoprotein/cholesterol atio, 
specific sheath size and duration of heparin treatment. Be- 
cause CAVEAT-I was not primarily designed to evaluate 
peripheral vascular complications, intensity of diagnostic 
workup was not controlled. It has been the experience of 
others (9), for example, that when duplex ultrasound is per- 
formed routinely in patients undergoing coronary intervention, 
the incidence of documented vascular complications may be 
higher. The impact that such a policy would have on the 
relative complication rates of coronary angioplasty and direc- 
tional coronary atherectomy is uncertain. 
Conclusions. There was no significant difference in in- 
hospital peripheral vascular complication rates between 
atherectomy and angioplasty inCAVEAT-I. Older age, female 
gender and the use ofpostinterventional heparin or intraaortic 
balloon counterpulsation were associated with a higher risk. 
The occurrence of peripheral vascular complications was asso- 
ciated with doubling of in-hospital costs and a much higher 
likelihood of death, myocardial infarction and repeat revascu- 
larization over 1 year. 
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